sever
acut
respiratori
syndrom
sar
caus
worldwid
outbreak
far
consensu
treatment
strategi
potenti
deadli
diseas
report
develop
standard
treatment
protocol
first
sar
patient
compris
antibiot
ribavirin
explain
rational
corticosteroid
regimen
deriv
titrat
dosag
achiev
satisfactori
clinic
respons
initi
patient
follow
prospect
observ
cohort
studi
aim
analys
detail
outcom
patient
treat
protocol
consecut
patient
admit
pamela
youd
nethersol
eastern
hospit
hong
kong
march
april
includ
analysi
diagnos
suffer
sar
ever
treat
standard
treatment
protocol
patient
fulfil
latest
definit
probabl
case
sar
world
health
organ
center
diseas
control
prevent
cdc
prospect
collect
demograph
data
exposur
histori
comorbid
present
featur
vital
sign
oxygen
requir
patient
studi
daili
blood
test
includ
haematolog
complet
blood
count
differenti
biochemistri
electrolyt
glucos
liver
renal
function
creatin
kinas
lactat
dehydrogenas
blood
sputum
urin
sampl
collect
routin
bacteriolog
studi
nasopharyng
sampl
collect
virolog
studi
includ
immunofluoresc
test
cultur
influenza
parainfluenza
respiratori
syncyti
adenovirus
clot
blood
sera
acut
convalesc
collect
serolog
studi
legionella
speci
chlamydia
pneumonia
mycoplasma
pneumonia
human
metapneumoviru
specif
look
hepat
b
surfac
antigen
hbsag
check
laboratori
diagnosi
coronaviru
perform
refer
laboratori
univers
hong
kong
central
public
health
laboratori
hong
kong
includ
nasopharyng
stool
sampl
revers
transcriptas
polymeras
chain
reaction
studi
coronavir
ribonucl
acid
rna
acut
convalesc
sera
test
parallel
igg
antibodi
cxr
patient
admiss
start
combin
treatment
start
puls
methylprednisolon
discharg
semiquantifi
use
score
system
previous
describ
lung
separ
six
section
upper
middl
lower
zone
medial
later
divis
score
scale
clear
subtl
hazi
mild
infiltr
appear
promin
infiltr
confluent
dens
opac
score
independ
perform
two
pulmonologist
blind
patient
clinic
inform
develop
treatment
protocol
sar
compris
antibiot
ribavirin
corticosteroid
final
dosag
regimen
corticosteroid
march
briefli
antibiot
levofloxacin
acid
plu
clarithromycin
given
suspect
sar
patient
combin
treatment
ribavirin
corticosteroid
start
follow
occur
extens
bilater
cxr
involv
ii
persist
cxr
involv
persist
high
fever
day
iii
clinic
cxr
laboratori
find
suggest
worsen
iv
oxygen
satur
room
air
ribavirin
given
day
per
protocol
mg
everi
h
mg
daili
intraven
least
day
stabil
mg
twice
daili
mg
daili
oral
corticosteroid
regimen
standard
follow
methylprednisolon
mgkg
daili
intraven
day
mgkg
daili
intraven
day
prednisolon
mgkg
daili
oral
day
mgkg
daili
oral
day
mgkg
daili
oral
last
day
addit
puls
methylprednisolon
mg
twice
daili
intraven
day
total
g
given
rescu
medic
case
respons
least
day
second
cours
antibiot
treat
possibl
sepsi
persist
lymphopenia
deterior
least
two
follow
three
paramet
clinic
condit
cxr
oxygen
satur
puls
therapi
standard
corticosteroid
regimen
tail
per
protocol
patient
gave
verbal
consent
treatment
follow
primari
outcom
studi
complianc
protocol
treatment
outcom
predictor
addit
therapi
puls
methylprednisolon
assist
ventil
time
clinic
stabil
clinic
stabil
defin
first
day
bodi
temperatur
persist
ii
room
air
persist
iii
requir
addit
therapi
defin
puls
corticosteroid
assist
ventil
complic
record
hyperglycaemia
denot
blood
glucos
level
mmoll
secondari
outcom
death
recoveri
interobserv
agreement
cxr
score
assess
plot
mean
score
use
subsequ
analysi
characterist
patient
group
compar
use
continu
variabl
test
categor
variabl
statist
signific
taken
p
independ
predictor
studi
multipl
logist
regress
forward
stepwis
entri
paramet
p
comparison
done
use
wilcoxon
test
analysi
test
done
identifi
predictor
time
clinic
stabil
continu
variabl
categor
use
median
valu
independ
predictor
studi
cox
proport
hazard
regress
analysi
forward
stepwis
entri
paramet
p
fulfil
assumpt
proport
hazard
confirm
surviv
plot
spss
inc
chicago
il
usa
version
use
analys
period
day
march
april
probabl
case
sar
admit
two
exclud
never
treat
accord
standard
protocol
one
transfer
anoth
hospit
continu
treatment
coronari
care
acut
myocardi
infarct
treatment
recoveri
characterist
patient
recruit
shown
tabl
six
prior
treatment
hospit
transfer
intens
care
treat
protocol
march
treat
de
novo
final
protocol
march
data
analys
detail
present
score
cxr
patient
plot
confirm
good
interobserv
agreement
fig
mean
sd
score
time
admiss
n
commenc
combin
treatment
ribavirin
methylprednisolon
n
puls
methylprednisolon
n
clinic
stabil
n
hospit
discharg
n
respect
posit
laboratori
diagnosi
infect
confirm
patient
group
c
greater
rise
igg
titr
convalesc
sera
mean
day
symptom
onset
sinc
coronavir
rna
test
pcr
viral
cultur
avail
april
nasopharyng
sampl
posit
stool
cultur
viru
admiss
five
patient
coinfect
organ
mycoplasma
pneumonia
n
haemophilu
influenza
n
klebsiella
speci
n
influenza
viru
n
compar
neg
sampl
patient
posit
nasopharyng
pcr
associ
longer
time
stabil
p
patient
receiv
antibiot
per
protocol
addit
acid
receiv
levofloxacin
six
clarithromycin
three
recov
antibiot
alon
nasophayng
aspir
posit
n
nasopharyng
aspir
pcr
sar
serolog
posit
n
stool
cultur
serolog
n
remain
given
standard
combin
treatment
day
symptom
onset
day
admiss
requir
addit
puls
methylprednisolon
day
two
requir
second
puls
day
commenc
combin
treatment
complianc
protocol
confirm
compar
administ
dose
drug
standard
regimen
ribavirin
mean
sd
daili
dose
mg
mgkg
bodyweight
intraven
mg
mgkg
oral
total
day
corticosteroid
methylprednisolon
administ
intraven
daili
dose
mgkg
follow
mgkg
day
prednisolon
oral
mgkg
follow
mgkg
mgkg
daili
total
day
puls
methylprednisolon
rescu
mg
intraven
per
patient
requir
corticosteroid
rescu
corticosteroid
dose
resum
puls
methylprednisolon
therapi
show
signific
deviat
standard
regimen
appropri
puls
methylprednisolon
rescu
confirm
follow
comparison
oxygen
requir
lmin
steroid
commenc
vs
lmin
puls
steroid
initi
p
cxr
score
vs
p
lymphocyt
count
vs
p
significantli
wors
start
puls
steroid
rescu
puls
methylprednisolon
rescu
requir
patient
given
combin
therapi
invas
ventil
comparison
characterist
commenc
combin
treatment
requir
requir
therapi
shown
tabl
multipl
logist
regress
show
independ
predictor
puls
methylprednisolon
rescu
age
adjust
odd
ratio
everi
year
increas
confid
interv
ci
p
ldh
adjust
elev
everi
iul
ci
p
independ
predictor
assist
invas
ventil
age
adjust
everi
year
increas
ci
p
need
oxygen
supplement
adjust
ci
p
creatinin
level
adjust
elev
everi
ci
p
time
median
se
clinic
stabil
patient
given
combin
therapi
estim
analysi
ci
day
symptom
onset
ci
day
commenc
combin
treatment
multivari
cox
regress
analysi
tabl
show
independ
predictor
longer
time
stabil
median
age
adjust
hazard
ratio
ci
p
delin
effect
outcom
age
stratifi
three
group
year
analysi
could
shown
older
age
group
took
longer
time
reach
clinic
stabil
fig
recruit
patient
ever
treat
combin
ribavirin
corticosteroid
signific
record
ribavirin
uncompl
hyperglycaemia
corticosteroid
occur
patient
eleven
develop
spontan
n
assist
ventil
n
patient
prescrib
second
cours
antibiot
piperacillintazobactam
treat
possibl
sepsi
manifest
fever
recrudesc
radiograph
andor
respiratori
deterior
treatment
two
patient
major
sepsi
due
pneumonia
acut
respiratori
distress
syndrom
one
due
staphylococcu
aureu
mrsa
subsequ
die
xanthomona
maltophilia
escherichia
coli
recov
patient
mrsa
elderli
also
one
tri
immunoglobulin
mgkgday
day
pentaglobin
biotest
pharma
gmbh
dreieich
germani
late
cours
ill
without
clinic
efficaci
none
patient
requir
antivir
immunomodul
agent
three
urinari
tract
infect
e
coli
n
group
b
streptococcu
n
none
six
patient
hepat
two
patient
transient
pancytopaenia
associ
posit
parvoviru
serolog
one
also
mild
haemolyt
anaemia
two
elderli
patient
diabet
mellitu
fatal
vascular
event
acut
myocardi
infarct
n
ischaem
brainstem
stroke
n
six
psychiatr
manifest
acut
confus
n
anxieti
depress
n
could
relat
corticosteroid
ill
per
se
outcom
patient
summar
tabl
juli
patient
observ
day
rang
admiss
one
death
attribut
sar
mrsa
pneumonia
two
due
comorbid
mortal
rate
seri
patient
age
age
cxr
survivor
significantli
clearer
discharg
score
vs
admiss
p
littl
residu
chang
score
score
discharg
patient
requir
oxygen
therapi
sar
relaps
report
outcom
patient
probabl
case
sar
infect
cohort
studi
repres
unselect
group
sar
patient
treat
standard
protocol
sinc
time
knowledg
diseas
still
scarc
given
uniform
intervent
could
evalu
detail
actual
dosag
efficaci
drug
administ
draw
infer
outcom
predictor
diseas
comparison
type
rout
dosag
drug
administ
uniform
report
seri
similar
seri
howev
inclus
appropri
intern
control
imposs
uneth
rapidli
evolv
outbreak
new
diseas
cohort
lower
mortal
rate
compar
report
seri
well
estim
overal
case
fatal
rate
sar
hong
kong
patient
younger
patient
age
older
cohort
zero
mortal
age
mortal
age
among
one
death
attribut
sar
present
demograph
clinic
characterist
patient
tabl
similar
wors
report
larger
seri
literatur
one
patient
receiv
pentaglobin
addit
immunomodulatori
agent
modal
experiment
treatment
eg
combin
convalesc
serum
therapi
sciclon
pharmaceut
inc
san
mateo
ca
usa
pentoxyfyllin
tumour
necrosi
factor
block
agent
etanercept
amgen
inc
thousand
oak
ca
usa
wyeth
pharmaceut
madison
nj
usa
infliximab
requir
patient
satisfactori
respons
standard
protocol
find
hbsag
carrier
state
advers
factor
lamivudin
use
prophylaxi
hepat
b
relaps
ventur
postul
therefor
differ
outcom
report
seri
could
possibl
relat
differ
detail
treatment
intervent
given
although
ribavirin
commonli
use
sar
outbreak
wide
believ
benefit
outcom
continu
use
ribavirin
continu
recoveri
patient
theoret
benefit
immunomodulatori
activ
drug
given
higher
dosag
major
advers
effect
occur
without
improv
outcom
therefor
think
ribavirin
per
se
unlik
reason
satisfactori
outcom
patient
howev
effect
ribavirin
present
studi
could
independ
assess
patient
receiv
corticosteroid
ribavirin
util
corticosteroid
sar
also
much
debat
activ
immun
system
acut
bacteri
viral
infect
known
stimul
product
cytokin
corticosteroid
decreas
releas
inflammatori
cytokin
anecdot
report
suggest
benefit
corticosteroid
manag
viral
pneumon
sinc
dose
regimen
employ
dissimilar
seri
believ
differ
time
dosag
durat
corticosteroid
use
may
account
differ
outcom
group
commenc
methylprednisolon
mean
day
symptom
onset
clinic
criteria
defin
priori
repres
excess
host
respons
fulfil
pathogenesi
sar
propos
compris
three
stage
name
viral
replic
lung
inflamm
fibrosi
base
assumpt
specul
treatment
criteria
enabl
patient
cover
agent
soon
onset
immun
lung
damag
anoth
seri
similar
combin
start
base
sole
lack
clinic
respons
antibiot
h
without
explicit
radiolog
criteria
even
earlier
patient
epidemiolog
histori
contact
mortal
author
state
underestim
sampl
bia
compar
higher
mortal
could
reflect
earlier
use
corticosteroid
without
consid
clinic
indic
onset
pulmonari
immunopatholog
damag
hypothesi
correct
time
would
possibl
still
pure
viral
replic
phase
patient
possibl
risk
increas
viral
load
without
correspond
benefici
effect
immunopatholog
lung
damag
nasopharyng
aspir
pcr
statu
aspir
predictor
mortal
anoth
seri
relationship
statu
time
stabil
patient
therefor
believ
appropri
time
steroid
commenc
could
import
factor
predict
outcom
experi
deriv
protocol
develop
suggest
start
corticosteroid
lower
dosag
may
abl
control
immunopatholog
lung
damag
sinc
persist
elev
proinflammatori
cytokin
may
promot
bacteri
prolifer
vitro
state
immun
balanc
achiev
appropriateoptim
corticosteroid
dosag
could
contribut
rel
low
rate
nosocomi
infect
anoth
sar
treatment
protocol
china
use
similar
corticosteroid
commenc
worsen
clinic
criteria
also
produc
lower
mortal
regimen
lower
dosag
seri
hong
kong
start
treatment
puls
methylprednisolon
mg
per
day
also
show
better
outcom
initi
mg
per
day
methylprednisolon
two
seri
appear
support
hypothesi
corticosteroid
requir
start
treatment
achiev
diseas
control
manag
unresolv
acut
respiratori
distress
syndrom
due
fibroprolifer
pneumocysti
carinii
pneumonia
desatur
cours
corticosteroid
least
day
recommend
experiment
acut
lung
injuri
shorter
corticosteroid
cours
may
compromis
recoveri
due
enhanc
accumul
collagen
discontinu
therapi
rapid
corticosteroid
withdraw
danger
cytokin
resurg
presenc
persist
upregul
receptor
also
observ
adequ
durat
corticosteroid
usag
necessari
prevent
rebound
sar
symptom
patient
receiv
corticosteroid
strictli
accord
standard
protocol
detail
steroid
taper
studi
usual
describ
vari
accord
individu
clinic
condit
variat
may
also
account
differ
patient
outcom
present
studi
control
studi
satisfactori
result
compar
seri
encourag
reason
success
howev
remain
specul
random
control
trial
suggest
confirm
efficaci
thank
jame
e
hansen
md
emeritu
professor
medicin
ucla
school
medicin
divis
respiratori
critic
care
physiolog
medicin
depart
medicin
medic
center
ca
usa
franki
choi
fhkam
radiolog
mrcp
head
depart
nuclear
medicin
pamela
youd
nethersol
eastern
hospit
hong
kong
sar
china
support
invalu
contribut
thank
bernard
kong
fhkam
medicin
consult
geriatrician
respiratori
physician
depart
medicin
pamela
youd
nethersol
eastern
hospit
arthur
e
varner
md
allergistclin
immunologist
allergi
diagnost
beachwood
oh
usa
chuang
md
pulmonologist
chang
gung
memori
hospit
taipei
taiwan
roc
tsui
fhkam
medicin
mrcp
cardiologist
depart
medicin
pamela
youd
nethersol
eastern
hospit
invalu
comment
manuscript
pang
frcpath
consult
pathologist
depart
patholog
pamela
youd
nethersol
eastern
hospit
yuen
frcpath
professor
microbiolog
univers
hong
kong
expert
advic
also
thank
hospit
colleagu
work
sar
ward
